Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $1.31B | $1.49B | $1.70B | $1.86B | $1.85B | $2.10B | $2.42B | $2.85B | $3.22B |
| Revenue growth | — | 17.6% | 13.5% | 14.3% | 9.2% | -0.8% | 13.5% | 15.4% | 18.0% | 12.9% |
| Operating income | -$803M | -$14.7M | -$124M | -$100M | -$43.4M | -$82.3M | $161M | $186M | $484M | $409M |
| Operating margin | -71.9% | -1.1% | -8.3% | -5.9% | -2.3% | -4.5% | 7.7% | 7.7% | 17.0% | 12.7% |
| Net income | -$630M | -$117M | -$77.2M | -$23.8M | $854M | -$64.1M | $142M | $168M | $427M | $349M |
| Net margin | -56.4% | -8.9% | -5.2% | -1.4% | 45.9% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (diluted) | -$3.81 | -$0.67 | -$0.44 | -$0.13 | $4.50 | -$0.35 | $0.75 | $0.87 | $2.21 | $1.80 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$228M | -$8.76M | $20.2M | $48.3M | $85.4M | $305M | $176M | $159M | $573M | $828M |
| Capital expenditures | $148M | $199M | $145M | $145M | $114M | $95.6M | $121M | $96.7M | $85.4M | $103M |
| Free cash flow | -$376M | -$208M | -$124M | -$96.8M | -$28.9M | $209M | $54.9M | $62.6M | $487M | $725M |
| Share buybacks | — | — | $0.00 | $0.00 | $50.0M | $0.00 | $0.00 | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $408M | $598M | $494M | $437M | $649M | $587M | $725M | $755M | $943M | $1.31B |
| Total assets | $4.02B | $4.63B | $4.43B | $4.69B | $5.85B | $6.00B | $6.38B | $6.84B | $6.99B | $7.59B |
| Total liabilities | $1.26B | $1.82B | $1.46B | $1.57B | $1.74B | $1.74B | $1.77B | $1.89B | $1.33B | $1.51B |
| Shareholders' equity | $2.77B | $2.81B | $2.97B | $3.12B | $4.10B | $4.27B | $4.60B | $4.95B | $5.66B | $6.09B |
| Retained earnings | -$1.52B | -$1.64B | -$1.69B | -$1.72B | -$862M | -$931M | -$789M | -$622M | -$195M | $154M |
| Shares (wtd avg diluted) | 166M | 174M | 177M | 179M | 192M | 183M | 189M | 192M | 197M | 197M |
Every figure is extracted from BIOMARIN PHARMACEUTICAL INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.